ESMO 2022 | Updates in melanoma at ESMO 2022
Paolo Ascierto, MD, National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses some of the key updates for melanoma at ESMO 2022, including the benefits of neoadjuvant pembrolizumab, the use of biomarkers and sequential treatment approaches, and the unmet needs of second-line treatment for patients with melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So during this ESMO we have seen several interesting new data. Two most important, the new adjuvant that we have seen during the Presidential. Now we can say that neoadjuvant is better than adjuvant because we have this small trial. With pembrolizumab given before surgery for 3 cycles then surgery then adjuvant, compared to surgery then adjuvant, with a good hazard ratio .59. It is really good for these patients...
So during this ESMO we have seen several interesting new data. Two most important, the new adjuvant that we have seen during the Presidential. Now we can say that neoadjuvant is better than adjuvant because we have this small trial. With pembrolizumab given before surgery for 3 cycles then surgery then adjuvant, compared to surgery then adjuvant, with a good hazard ratio .59. It is really good for these patients. No problem in terms of safety. So neoadjuvant probably will become the standard-of-care. These patients with palpable lymph node.
The other interesting data come from another phase two trial with the TIL, the T-cell therapy. It was compared to ipilimumab but there was an important advantage. This confirmed what we have seen with another trial with the Lifileucel. It was presented at ASCO. So these are the two important data. It’s not the case that they were discussing during the Presidential.
But then we’ve seen also other interesting data. We’ve seen some interesting about biomarkers. We have seen interesting data for the sequential approach, the SECOMBIT and also an update about the adjuvant trial with pembrolizumab and even saw other update of clinical trial.
So the question for the future will be if we can improve the outcome in the adjuvant. We have now a trial of nivolumab and relatlimab. We’ll see. The neoadjuvant good data from pembro. We are waiting now the results from NADIM. Another trial, we said ipi-nivo is adjuvant. The second line is the setting where we need to do more with new combination. We’ll see if there are drug that can increase. We have seen during disease more the failure of the BEMPEG. That probably was the wrong PEG-IL-2. But there are other compounds like the pembro plus lenvatinib or new target, the vaccine probably can increase the benefit for our patients.
Read more...
